| ADC | Antibody drug conjugate |
| ATP | Adenosine triphosphate |
| BBB | Blood brain barrier |
| BiTE | Bispecific T-cell engager |
| CDK | Cyclin-dependent kinase |
| CNS | Central nervous system |
| CSF | Cerebrospinal fluid |
| CYP | Cytochrome P450 |
| ecDNA | Extrachromosomal DNA |
| EGF | Epidermal growth factor |
| EGFR | Epidermal growth factor receptor |
| EIAED | Enzyme inducing antiepileptic drug |
| EORTC | European Organization for Research and Treatment of Cancer |
| ErbB | Erb-b2 receptor tyrosine kinase |
| FISH | Fluorescence in situ hybridization |
| GBM | Glioblastoma |
| Grb2 | Growth factor receptor-bound protein 2 |
| HB-EGF | Heparin-binding EGF-like growth factor |
| HER | Human epidermal growth factor receptor |
| IC50 | Half maximal inhibitory concentration |
| IGFR1 | Insulin growth factor receptor 1 |
| IHC | Immunohistochemistry |
| INSIGhT | Individualized Screening Trial of Innovative Glioblastoma Therapy clinical trial |
| JAK | Janus kinase |
| KLH | Keyhole limpet hemocyanin |
| KRAS | Kirsten rat sarcoma |
| MAPK | Mitogen-activated protein kinase |
| MET | MET receptor tyrosine kinase; also known as hepatocyte growth factor receptor |
| MGMT | Enzyme O6-methylguanine-DNA methyltransferase |
| MMAF | Monomethyl auristatin F |
| MRI | Magnetic resonance imaging |
| NABTC | North American Brain Tumor Consortium |
| NCCTG | North Central Cancer Treatment Group |
| NSCLC | Non-small cell lung cancer |
| OS | Overall survival |
| PDB | Protein Database |
| PI3K | Phosphoinositide-3 kinase |
| PFS | Progression free survival |
| PKB | Protein kinase B; also known as Akt |
| PKC | Protein kinase C |
| PLCγ | Phospholipase C γ |
| RET | Rearranged during transfection |
| RT | Radiotherapy |
| RTOG | Radiation Therapy Oncology Group |
| SPECT | Single-photon emission computed tomography |
| STAT | Signal transducer and activator of transcription |
| TGF-α | Transforming growth factor-α |
| TKI | Tyrosine kinase inhibitor |
| TMZ | Temozolomide |